Zdrowie i gospodarka · 15/10/2007

FDA Releases Draft Guidance on Postmarketing Adverse Event Reporting for Nonprescription Human Drugs

The Food and Drug Administration (FDA) has published a draft guidance document outlining requirements for reporting postmarketing serious adverse events for nonprescription human drugs marketed without an approved application.